Kairos Pharma Reports $1.654 Million Net Loss in Q1 2026, No Revenue Generated

Kairos Pharma, Ltd. reported its financial results for the first quarter of 2026, revealing a net loss of $1.654 million, compared to a net loss of $1.262 million for the same period in 2025. The company did not generate any revenue during the quarter, maintaining its status as a clinical-stage biopharmaceutical firm focused on developing immunotherapy and cell therapy treatments for oncology. Operating expenses increased to $1.690 million from $1.266 million year-over-year, primarily driven by higher research and development costs associated with ongoing clinical trials.

The company's total assets decreased to $5.744 million as of March 31, 2026, down from $6.540 million at the end of 2025. This decline was attributed to a reduction in cash and cash equivalents, which fell to $3.675 million from $4.491 million. Current liabilities also increased, with accounts payable and accrued expenses rising to $431,000 from $199,000. Shareholders' equity decreased to $5.313 million, reflecting an accumulated deficit of $15.916 million.

In terms of strategic developments, Kairos Pharma engaged in an At the Market (ATM) offering, raising $385,000 through the sale of 589,845 shares of common stock. The net proceeds from this offering were $367, after deducting offering costs. The company also entered into a Pharmaceutical Development Services Agreement with Brammer Bio MA, LLC, committing $783,000 for the manufacturing of clinical supplies for its ENV-105 product, which is currently in Phase II trials.

Operationally, the company reported an increase in research and development expenses, which rose to $684,000 from $493,000 in the previous year, reflecting the costs associated with its clinical trials. General and administrative expenses also increased to $1.006 million from $773,000, largely due to higher professional service fees related to its status as a public company. As of March 31, 2026, the company had 21,411,198 shares outstanding, up from 20,821,353 shares at the end of 2025.

Looking ahead, Kairos Pharma indicated that it expects to continue incurring significant operating losses as it advances its product candidates through clinical development. The company highlighted the need for substantial additional funding to support its operations and growth strategy, emphasizing that it may pursue public or private equity offerings, debt financings, and potential collaborations to meet its financial needs. The company cautioned that its ability to continue as a going concern is dependent on its success in raising additional funds and implementing its strategic initiatives.